Treatment with tofacitinib immediately after CD4+ transfer resulted in an enhanced expansion of inflammatory CD4+ T cells and did not prevent occurrence of colitis, however, treatment after start of symptoms of colitis ameliorated disease activity on a clinical basis and histological analyses. This evidence concerns the gene CD4 and colitis.